arrow
F

Francesca Ligorio

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:17
被引数:938

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world Effectiveness of CDK4/6 Inhibitors in Older Patients with HR+/HER2- Advanced Breast Cancer: a sub-analysis of the multicenter, PALMARES-2 study

CDK4/6抑制剂在HR+/HER2-晚期乳腺癌老年患者中的真实世界有效性:一项多中心PALMARES-2研究的子分析

2026-06-010
OAAI
Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomes

I期三阴性乳腺癌的辅助化疗:生存结局的系统评价与Meta分析

2026-05-140
PRE
Fasting boosts breast cancer therapy efficacy via glucocorticoid activation

禁食通过糖皮质激素激活增强乳腺癌治疗效果

Nature
IF48.5
2025-12-100
OAAI
Antitumor immunological benefits of Vitamin E analogue δ-tocotrienol in early breast cancer patients depend on body mass index: results from the TOCANNATO window-of-opportunity trial

维生素E类似物δ-tocotrienol在早期乳腺癌患者中的抗肿瘤免疫益处取决于体重指数:TOCANNATO窗口期机会试验的结果

BREAST
IF7.9
2025-02-010
OAAI
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

CD36富集在HER2阳性间充质干细胞中,驱动乳腺癌的治疗抵抗性

2025-01-201
OA
Modulation of systemic and intratumor metabolism predicts response to fasting-mimicking diet plus chemotherapy in patients with early TNBC

系统性及肿瘤内代谢的调控预测了空腹模拟饮食联合化疗对早期TNBC患者的反应

2024-09-010
PRE
Precocious modulation of metabolic and immunological parameters predicts tumor response to fastingmimicking diet plus chemotherapy in patients with early stage TNBC
2024-05-021
PRE
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

外周血淋巴细胞预测接受CDK4/6抑制剂治疗的激素受体阳性HER2-negative晚期乳腺癌患者的临床结局

2023-12-201
OAAI
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities
2023-10-013
PRE
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial
2023-08-248
OAAI
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023-04-1715
OAAI
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
2023-04-1310
OAAI
HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy
2023-03-013
PRE